Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer response to questions on M&A -> add value to company

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 21, 2022 2:42pm

168 Views

Post# 35039709

RE:RE:RE:RE:RE:Pfizer response to questions on M&A -> add value to company

So here is the original post that starrted today's responses ...

Oct. 20, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven") announced today the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share.

https://www.biospace.com/article/releases/biohaven-announces-pricing-of-public-offering-of-common-shares-october-21-2022/

Pfizer acquired all of the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, for a total transaction consideration of approximately $11.6 billion. As a result of the acquisition, Biohaven became a wholly-owned subsidiary of Pfizer.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals

As a result of Pfizer's US$11.6 Billion acquisition, Biohaven became a wholly-owned subsidiary of Pfizer and is now raising capital to continue its operation.

This development can serve as a roadmap on how ONCY can continue contributing to the development of pelareorep in multiple cancers, in combination with multiple I/O agents, in multiple indications, associated with the treatment of multiple unmet needs in liquid and solid tumor cancers.

And a cash raise post acquisition is not something that anyone who is intent on pushing a negative narrative is interested in hearing.

<< Previous

Bullboard Posts

Next >>

Kraken finds 50+ mine-like targets with MINSAS in naval exercise